- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
* NEWS * 05 August 2019 * Correction 03 June 2020 * Correction 03 June 2020 Despite slow uptake in the clinic, liquid biopsy tests incorporating methylation and other signatures are showing
increasingly compelling data for non-invasive detection of cancer. By * Cormac Sheridan0 * Cormac Sheridan * Dublin, Ireland Liquid-biopsy platforms, which have long faced considerable
scepticism as to their utility in clinical practice, are attracting a new bout of intense investor interest. ACCESS OPTIONS Access Nature and 54 other Nature Portfolio journals Get Nature+,
our best-value online-access subscription $29.99 / 30 days cancel any time Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Rent or
buy this article Prices vary by article type from$1.95 to$39.95 Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: _Nature Biotechnology_
37, 972-974 (2019) _doi: https://doi.org/10.1038/d41587-019-00022-7_ UPDATES & CORRECTIONS * CORRECTION 03 JUNE 2020: An earlier version of this article omitted mention in Table 1 of
Guardant360’s FDA breakthrough device designation 15 February 2018 * CORRECTION 03 JUNE 2020: The Table 1 incorrectly stated that MirXes’ products were at research stage when GastroClear has
been available in Singapore since its approval on 9 May 2019 by the Singapore by the Health Sciences Authority.
